CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 624 enrolled
Drug / intervention
chemotherapydrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00382018
NCT00382018Phase 3Completed

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment

SWOG Cancer Research Network·interventional·Posted Sep 28, 2006·Updated Nov 6, 2017

In Brief

A Phase 3 clinical trial evaluating chemotherapy for Breast Cancer. Completed, enrolled 624 participants across 296 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Measuring blood levels of tumor cells may help in learning how well chemotherapy works to kill metastatic breast cancer cells and allow doctors to plan better treatment. When blood levels of tumor cells are high while receiving chemotherapy, it is not yet known whether it is more effective to change chemotherapy regimens at that time or wait until disease progression. PURPOSE: This randomized phase III trial is studying treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2015
Study CompletionJul 11, 2017
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 19.8 years ago

Interventions

chemotherapydrug

No administration details available